Skip to main content
PMC home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2005 Sep;81(959):586–588. doi: 10.1136/pgmj.2004.030841

Assessment of the efficacy of total lymphocyte counts as predictors of AIDS defining infections in HIV-1 infected people

J Stebbing 1, S Sawleshwarkar 1, C Michailidis 1, R Jones 1, M Bower 1, S Mandalia 1, M Nelson 1, B Gazzard 1
PMCID: PMC1743346  PMID: 16143689

Abstract

Background: The CD4 count is a dominant prognostic and predictive factor in HIV infection. This study assessed the utility of the total lymphocyte count (TLC) in place of the CD4 count to predict the development of AIDS defining opportunistic infections (ADOI).

Methods: The Chelsea and Westminster cohort was used to identify those people with a first episode of an ADOI. Corresponding CD4 and TLCs were recorded before diagnosis or at the time of first prescribing prophylaxis; patients without an AIDS defining opportunistic infection were defined as being at "risk" and receiver operating characteristic (ROC) curves were used to display the results of sensitivity and the false positive error rate of total lymphocyte and CD4 count groups.

Results: A significant linear correlation was seen between the log10 CD4 count and log10 TLC (Pearson's correlation coefficient = 0.70, p<0.001). The finer cut off value for TLC where false positive error rate is minimum and sensitivity maximum was 1500–2000 cells/mm3. Patients with TLC 1000–1500 cells/mm3 were estimated to be at 40% increased risk of developing an ADOI. The cut off value for CD4 counts measured 200 cells/mm3 above which the risk developing an ADOI decreased. Patients with a CD4 count of 150–200 cells/mm3 were at a 34% increased risk of developing an ADOI. The area under the ROC curve for TLC was 10% lower than that for CD4 count.

Conclusions: The TLC is minimally less reliable than the CD4 count as a predictor of ADOIs. In the absence of expensive equipment for CD4 measurement, the TLC is a useful test.

Full Text

The Full Text of this article is available as a PDF (62.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brown M., Wittwer C. Flow cytometry: principles and clinical applications in hematology. Clin Chem. 2000 Aug;46(8 Pt 2):1221–1229. [PubMed] [Google Scholar]
  2. Chaisson R. E., Keruly J. C., Moore R. D. Association of initial CD4 cell count and viral load with response to highly active antiretroviral therapy. JAMA. 2000 Dec 27;284(24):3128–3129. doi: 10.1001/jama.284.24.3128. [DOI] [PubMed] [Google Scholar]
  3. Diagbouga S., Durand G., Sanou P. T., Dahourou H., Ledru E. Evaluation of a quantitative determination of CD4 and CD8 molecules as an alternative to CD4+ and CD8+ T lymphocyte counts in Africans. Trop Med Int Health. 1999 Feb;4(2):79–84. doi: 10.1046/j.1365-3156.1999.00362.x. [DOI] [PubMed] [Google Scholar]
  4. Egger Matthias, May Margaret, Chêne Geneviève, Phillips Andrew N., Ledergerber Bruno, Dabis François, Costagliola Dominique, D'Arminio Monforte Antonella, de Wolf Frank, Reiss Peter. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002 Jul 13;360(9327):119–129. doi: 10.1016/s0140-6736(02)09411-4. [DOI] [PubMed] [Google Scholar]
  5. Hammer Scott M. Increasing choices for HIV therapy. N Engl J Med. 2002 Jun 27;346(26):2022–2023. doi: 10.1056/NEJM2p020052. [DOI] [PubMed] [Google Scholar]
  6. Hirschel Bernard. Antiretroviral treatment and research in resource-poor countries. Lancet. 2003 Feb 1;361(9355):434–435. doi: 10.1016/S0140-6736(03)12414-2. [DOI] [PubMed] [Google Scholar]
  7. Janossy George. Dried blood spot technology for CD4+ T-cell counting. Lancet. 2004 Mar 27;363(9414):1074–1075. doi: 10.1016/S0140-6736(04)15849-2. [DOI] [PubMed] [Google Scholar]
  8. Mwaba Peter, Cassol Sharon, Pilon Rick, Chintu Chifumbe, Janes Michelle, Nunn Andrew, Zumla Alimuddin. Use of dried whole blood spots to measure CD4+ lymphocyte counts in HIV-1-infected patients. Lancet. 2003 Nov 1;362(9394):1459–1460. doi: 10.1016/S0140-6736(03)14693-4. [DOI] [PubMed] [Google Scholar]
  9. Palella F. J., Jr, Delaney K. M., Moorman A. C., Loveless M. O., Fuhrer J., Satten G. A., Aschman D. J., Holmberg S. D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998 Mar 26;338(13):853–860. doi: 10.1056/NEJM199803263381301. [DOI] [PubMed] [Google Scholar]
  10. Porter Kholoud, Babiker Abdel, Bhaskaran Krishnan, Darbyshire Janet, Pezzotti Patrizio, Porter Kholoud, Walker A. Sarah, CASCADE Collaboration Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet. 2003 Oct 18;362(9392):1267–1274. doi: 10.1016/s0140-6736(03)14570-9. [DOI] [PubMed] [Google Scholar]
  11. Rabkin Miriam, El-Sadr Wafaa, Katzenstein David A., Mukherjee Joia, Masur Henry, Mugyenyi Peter, Munderi Paula, Darbyshire Janet. Antiretroviral treatment in resource-poor settings: clinical research priorities. Lancet. 2002 Nov 9;360(9344):1503–1505. doi: 10.1016/S0140-6736(02)11478-4. [DOI] [PubMed] [Google Scholar]
  12. Sabin C. A., Lampe F. C., Chaloner C., Madge S. J., Lipman M. C. I., Youle M., Phillips A. N., Johnson M. A. An audit of antiretroviral treatment use in HIV-infected patients in a London clinic: the limitations of observational databases when auditing antiretroviral treatment use. HIV Med. 2003 Apr;4(2):87–93. doi: 10.1046/j.1468-1293.2003.00141.x. [DOI] [PubMed] [Google Scholar]
  13. Shapiro Howard M., Mandy Francis F., Rinke de Wit Tobias F., Sandstrom Paul. Dried blood spot technology for CD4+ T-cell counting. Lancet. 2004 Jan 10;363(9403):164–165. doi: 10.1016/S0140-6736(03)15270-1. [DOI] [PubMed] [Google Scholar]
  14. Stebbing Justin, Gazzard Brian, Douek Daniel C. Where does HIV live? N Engl J Med. 2004 Apr 29;350(18):1872–1880. doi: 10.1056/NEJMra032395. [DOI] [PubMed] [Google Scholar]
  15. Taha T. E., Graham S. M., Kumwenda N. I., Broadhead R. L., Hoover D. R., Markakis D., van Der Hoeven L., Liomba G. N., Chiphangwi J. D., Miotti P. G. Morbidity among human immunodeficiency virus-1-infected and -uninfected African children. Pediatrics. 2000 Dec;106(6):E77–E77. doi: 10.1542/peds.106.6.e77. [DOI] [PubMed] [Google Scholar]
  16. Woods G. L. Automation in clinical microbiology. Am J Clin Pathol. 1992 Oct;98(4 Suppl 1):S22–S30. [PubMed] [Google Scholar]
  17. Yeni Patrick G., Hammer Scott M., Carpenter Charles C. J., Cooper David A., Fischl Margaret A., Gatell Jose M., Gazzard Brian G., Hirsch Martin S., Jacobsen Donna M., Katzenstein David A. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2002 Jul 10;288(2):222–235. doi: 10.1001/jama.288.2.222. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES